electroCore, Inc. (ECOR): Price and Financial Metrics

electroCore, Inc. (ECOR)

Today's Latest Price: $0.93 USD

0.00 (-0.05%)

Updated May 29 4:00pm

Add ECOR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ECOR Stock Summary

  • ECOR's went public 1.94 years ago, making it older than merely 4.27% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of -57.35%, electroCore Inc's debt growth rate surpasses just 4.47% of about US stocks.
  • The volatility of electroCore Inc's share price is greater than that of 96.16% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to electroCore Inc are TRUE, QTRX, EKSO, SNES, and IGC.
  • ECOR's SEC filings can be seen here. And to visit electroCore Inc's official web site, go to www.electrocore.com.
ECOR Daily Price Range
ECOR 52-Week Price Range

ECOR Stock Price Chart More Charts

ECOR Price/Volume Stats

Current price $0.93 52-week high $5.64
Prev. close $0.93 52-week low $0.32
Day low $0.89 Volume 604,842
Day high $0.97 Avg. volume 1,144,438
50-day MA $0.89 Dividend yield N/A
200-day MA $1.49 Market Cap 35.44M

electroCore, Inc. (ECOR) Company Bio

electroCore, LLC, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. It is developing gammaCore, a prescription-only vagus nerve stimulation therapy, for the acute treatment of pain associated with migraine and episodic cluster headache in adults. The company was founded in 2005 and is based in Basking Ridge, New Jersey.

ECOR Latest News Stream

Event/TimeNews Detail
Loading, please wait...

ECOR Latest Social Stream

Loading social stream, please wait...

View Full ECOR Social Stream

Latest ECOR News From Around the Web

Below are the latest news stories about electroCore Inc that investors may wish to consider to help them evaluate ECOR as an investment opportunity.

electroCore, Inc. to Present at Little Grapevine’s G1 Microcap Virtual Conference

BASKING RIDGE, N.J., May 29, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that that a prerecorded virtual presentation featuring Dan Goldberger, Chief Executive Officer, will be available at Little Grapevine™ (www.littlegrapevine.com) beginning today, May 29, 2020, at 10:30 a.m. Eastern Standard Time. Accompanying the presentation will be a short executive introduction, as well as a brief Q&A with Mr. Goldberger. No fee is required to join or view the company’s Little Grapevine Conference presentation, as it is open to the public.

Yahoo | May 29, 2020

electroCore: Promising Product Means New Management Team Can Complete Unlikely Turnaround

Investment Thesis electroCore share price performance since IPO. Source: TradingView. electroCore (NASDAQ:ECOR) has been a crushing disappointment for its investors since its June 2018 IPO. Despite the promise of its FDA approved, non-invasive treatment for migraines - gammaCore - cleared for the acute and preventive treatment of migraines and episodic...

Edmund Ingham | May 28, 2020

ElectroCore, Inc. (ECOR) Reports Q1 Loss, Tops Revenue Estimates

electroCore, Inc. (ECOR) delivered earnings and revenue surprises of -4.00% and 0.55%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research | May 14, 2020

electroCore Announces First Quarter Financial Results

BASKING RIDGE, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced first quarter 2020 financial results and provided an operational update. Received 510(k) clearance from FDA to expand the gammaCore label into migraine prevention. Announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and Technology Payment (ITP) Program for the use of gammaCore (nVNS) in the treatment of cluster headache in adults, through September 2020.

Yahoo | May 14, 2020

electroCore to Announce First Quarter Ended March 31, 2020 Financial Results on Thursday, May 14

BASKING RIDGE, N.J., May 07, 2020 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for.

Yahoo | May 7, 2020

Read More 'ECOR' Stories Here

ECOR Price Returns

1-mo -1.10%
3-mo 26.88%
6-mo -39.22%
1-year -45.61%
3-year N/A
5-year N/A
YTD -41.51%
2019 -74.60%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9255 seconds.